Glenmark Expands US Portfolio With Milnacipran Launch And FDA Approval

The company’s latest milestones reflect its dual focus on expanding therapeutic offerings and securing regulatory approvals in competitive segments. With Milnacipran Hydrochloride tablets and an OTC nasal spray now added to its portfolio, Glenmark is positioned to enhance accessibility and affordability for patients in the US.

Milnacipran Hydrochloride Launch
Milnacipran Hydrochloride tablets, used in the management of fibromyalgia, have been introduced in multiple strengths. This launch underscores Glenmark’s commitment to addressing chronic conditions with cost-effective treatment options.

FDA Approval For Nasal Spray
The US FDA has granted final approval for Glenmark’s Fluticasone Propionate Nasal Spray USP, 50 mcg per spray, an over-the-counter product widely used for allergy relief. This approval opens new opportunities in the consumer healthcare segment.

Key Highlights

• Glenmark launches Milnacipran Hydrochloride tablets in the US
• Multiple strengths available for fibromyalgia treatment
• Receives final US FDA approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
• Strengthens generics and OTC portfolio in the US market

Sources: Company announcement, regulatory filings